More Videos
SPECIAL REPORT
MOST SHARED
- The 'Real' Jobless Rate: 17.5% Of Workers Are Unemployed
- Existing-Home Sales Jump To Highest Level in 2-1/2 Years
- Wave of Debt Payments Facing US Government
- Paul: Audit the Fed
- Start-Up Proves Everything Really Is Better With Bacon
- TV Retailer QVC Joins 'Black Friday' Frenzy
- Buffett's Wealth and Fame Hasn't Helped 'Warren' As a Name
- S&P Stocks Trading at New 52-Week Highs
- Madoff—The Holiday Drink
- China Asks Its Banks to Slow Down
- Rally Could 'Have Some Legs in 2010': Market Strategist
- Investors May Skew Housing Reality
- Buffett's Wealth and Fame Hasn't Helped 'Warren' As a Name
- Are Crazy Retail Deals Good for Business?
- Expect a 'Square Root-Shaped' Recovery: Chief Investor
- Madoff—The Holiday Drink
- HP to Feed on Enterprise Spending Next Year: Tech Analyst
- Busch: Markets Smell a Country Rat
- Schork Oil Outlook: Mission Impossible For The Bears?
- Bear, Lehman Execs Weren't Wiped Out by Crisis: Study
- How Real Estate Investors Skew Housing's Reality
- Even Buffett's Huge Fame Can't Help the Name 'Warren'
- Wave of Debt Payments Facing US Government
- US Job Losses to Bottom out Next Quarter: NABE
- Obama Jobs Forum May Be More Political Than Practical
- Maria Blog: Are Crazy Retail Deals Good for Business?
- Suze Orman’s 'A Healthier, Wealthier You'
- Latest Holiday Drinks: The Madoff...and the TARPatini
PHARMA'S MARKET VIDEO
Cholesterol Drug Battle: Niaspan vs. Zetia 
16 Nov 2009Cardiologist Grades Cholesterol Drug Study 16 Nov 2009
Merck's Cholesterol Drugs Under Pressure 16 Nov 2009
Cholesterol Drug Battle: Merck vs. Abbott Labs 16 Nov 2009
Cholesterol Drug Battle 16 Nov 2009
Novo Nordisk CEO on Diabetes Epidemic 13 Nov 2009
RSS FEED
Pharma's Market
Text Size 
 |
AP |
] over whether it beat, met or missed its earnings pre-announcement earlier this month, analysts are putting out research notes to clients on the company's results, guidance and new drug data and blog readers are sending emails about my take on the full year 2007 number. Analyst reviews are mixed.
Lazard Capital Markets' Joel Sendek is keeping his Hold rating on AMGN. He writes: "Sales declines in (the anemia drug) business seem to be slowing, but too early to call a bottom in advance of March ODAC meeting."
ODAC is the abbreviation for the Food and Drug Administration Advisory Committee that will be meeting to talk about the risks of the anemia drugs on cancer patients. The products are used to combat the side effects of chemotherapy. While Wachovia's George Farmer who rates the stock an Outperform says he believes "pressures should lighten this year" on the anemia drugs.
Leerink Swann's Bill Tanner, who also thinks AMGN is an outperformer, writes: "We believe investors will once again revisit AMGN shares by virtue of the valuation and better business prospects beyond 2008."
But others are more cautious. Bernstein's Geoffrey Porges is keeping a Market-perform rating on the stock arguing: "We continue to view the mid March (FDA panel) meeting with great trepidation, and...would prefer to remain on the sidelines pending resolution of this overhang."
FBR's Jim Reddoch is also neutral on the shares and he agrees that the upcoming FDA meeting means "there is still downside potential if the (anemia drug) label is tightened."
Miller Tabak's Les Funtleyder writes: "The company is still a financial story rather than a science story so we Reit(erate) Neutral." And Rodman & Renshaw's Mike King cautions, "Further declines (in anemia drug sales) could result depending on the outcome of the March 13 ODAC panel."
FBR, Lazard, Wachovia, Leerink Swann, Bernstein and R & R make a market in AMGN.
Meantime, blog readers are nearly unanimous in their opinion that my interpretation of the company's guidance and my protestation of Amgen's response to my report were wrong.
Dean Smith of Bellevue, WA writes: "You're an idiot."
That's not an excerpt. That's the entire text.
Kirk Johnson says: "Why would you assume that 'close to the low end' means 'above the lower end' rather than 'somewhere close to $4.30'?"
Steve Silverman writes: "It's not becoming of you. Let it sleep man!"
And Darry Schroader says: "It was typical Huckman reporting, couldn't dwell on anything positive just try to put something negative into play."
As I write this, AMGN shares are rallying.
Questions? Comments?
Data is a real-time snapshot *Data is delayed at least 15 minutes